Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Senhwa Biosciences, Inc.
Study ID
NCT03897036
Phase
PHASE1
Status
Completed

Conditions

  • Carcinoma, Basal Cell

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CX-4945 — DRUG
    API powder-in-capsule in 200 mg strength

Study Details

This study is to determine the recommended phase II dose (RP2D) and schedule of CX-4945 when administered orally twice daily for 28 consecutive days, in a 4-week (28 days) cycle, in patients with locally advanced or metastatic basal cell carcinoma (BCC). The safety and tolerability of CX-4945, preliminary evidence of antitumor effect, and the effect of CX-4945 treatment on the Hh signaling pathway will also be evaluated in this study.

Key Dates

Start date
Apr 16, 2019
Status verified
May 2025
Primary completion
Jan 25, 2024
Completion
Jan 25, 2024

Study Design

Enrollment
25 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment-Duration-Increment
    CX-4945 capsules at 1000mg BID x 28 days/cycle
  • Experimental: Expansion
    CX-4945 capsules at 1000mg BID x 28 days/cycle

Primary Outcome Measure

Determination of RP2D [ Time Frame: Cycle 1, twenty-eight (28) day continuous dosing schedule ]

Locations (6)

Find similar trials in Scottsdale, AZ